Isomorphic Labs Raises $5 Billion Before Its First Drug Reaches a Clinical Trial
Greenoaks and Sequoia co-led the Series C announced on 17 November, with Alphabet investing again. Isomorphic gave no valuation, though Bloomberg reported talks at about $50 billion. Its drug candidates are still preclinical.



